Status:
COMPLETED
A Comparative Study of KSO-0400 in BPH Patients With LUTS
Lead Sponsor:
Kissei Pharmaceutical Co., Ltd.
Conditions:
Benign Prostatic Hyperplasia (BPH)
Eligibility:
MALE
50+ years
Phase:
PHASE2
Brief Summary
The objective of this study is to evaluate the efficacy and safety of KSO-0400 compared to placebo for the treatment of LUTS caused by BPH.
Eligibility Criteria
Inclusion
- BPH patients with LUTS
Exclusion
- Patients with a history of prostatectomy, intrapelvic radiation therapy, thermotherapy of prostate or prostatic hyperthermia
- Patients with prostate cancer or suspected prostate cancer
- Patients who have any clinically relevant cardiovascular, hepatic or renal disorder
Key Trial Info
Start Date :
Trial Type :
INTERVENTIONAL
End Date :
Estimated Enrollment :
400 Patients enrolled
Trial Details
Trial ID
NCT01222650
Last Update
July 4 2011
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Japan
Kanto Region, Japan